117.62
price up icon0.15%   0.18
after-market アフターアワーズ: 117.01 -0.61 -0.52%
loading
前日終値:
$117.44
開ける:
$117.46
24時間の取引高:
1.03M
Relative Volume:
1.06
時価総額:
$11.84B
収益:
$2.24B
当期純損益:
$385.90M
株価収益率:
63.24
EPS:
1.86
ネットキャッシュフロー:
$440.10M
1週間 パフォーマンス:
-7.51%
1か月 パフォーマンス:
-0.33%
6か月 パフォーマンス:
-17.34%
1年 パフォーマンス:
+7.97%
1日の値動き範囲:
Value
$116.33
$118.31
1週間の範囲:
Value
$116.33
$128.24
52週間の値動き範囲:
Value
$108.14
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1204)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
1,448
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NBIX 117.62 11.84B 2.24B 385.90M 440.10M 1.86
ZTS 176.42 79.51B 9.15B 2.43B 2.31B 4.92
TAK 13.53 42.89B 30.27B 1.93B 3.45B 0.444
HLN 9.43 42.57B 14.26B 1.55B 0 0.3327
TEVA 16.49 18.51B 16.77B -959.00M 1.37B -2.00
VTRS 13.00 15.37B 15.24B -646.50M 1.88B 1.53

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Nov 17, 2024

Empowered Funds LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 17, 2024
pulisher
Nov 17, 2024

Sumitomo Mitsui Trust Group Inc. Sells 11,502 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Impax Asset Management Group plc Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

GSA Capital Partners LLP Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Boosted by Plato Investment Management Ltd - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Aigen Investment Management LP Purchases Shares of 5,948 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

(NBIX) Trading Report - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Principal Financial Group Inc. Sells 120,576 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga

Nov 12, 2024
pulisher
Nov 12, 2024

Neurocrine Biosciences: Healthcare Marketing Impact Awards 2024 - Modern Healthcare

Nov 12, 2024
pulisher
Nov 12, 2024

Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch

Nov 12, 2024
pulisher
Nov 12, 2024

How Neurocrine Biosciences helps health care professionals diagnose a movement disorder - Ad Age

Nov 12, 2024
pulisher
Nov 11, 2024

On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned - BioPharma Dive

Nov 11, 2024
pulisher
Nov 11, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Los Angeles Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 10, 2024
pulisher
Nov 08, 2024

Fiera Capital Corp Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels (NASDAQ:NBIX) - Seeking Alpha

Nov 08, 2024
pulisher
Nov 08, 2024

Summit Global Investments Sells 24,024 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality - Yahoo Finance Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Beacon Harbor Wealth Advisors Inc. Buys Shares of 47,917 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Kornitzer Capital Management Inc. KS Makes New $3.59 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Neurocrine Biosciences presents new KINECT®-HD data showing consistent efficacy across 19 subgroups and improvements in aspects of emotional health with Ingrezza (valbenazine) capsules - PharmaLive

Nov 07, 2024
pulisher
Nov 07, 2024

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PR Newswire

Nov 07, 2024
pulisher
Nov 07, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Van ECK Associates Corp - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nisa Investment Advisors LLC - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 06, 2024

Impax Asset Management Group plc Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Neurocrine Biosciences to Participate at Investor Conferences in November - PR Newswire

Nov 05, 2024
pulisher
Nov 05, 2024

Neurocrine Biosciences' SWOT analysis: navigating challenges in a competitive biotech stock landscape - Investing.com

Nov 05, 2024
pulisher
Nov 05, 2024

Positive results for Neurocrine’s Ingrezza in tardive dyskinesia - The Pharma Letter

Nov 05, 2024
pulisher
Nov 05, 2024

AlphaCentric Advisors LLC Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Neurocrine (NBIX) to Present at 3 Major Healthcare Conferences in November | NBIX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules - PR Newswire

Nov 04, 2024
pulisher
Nov 04, 2024

Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Cantor Fitzgerald Has Weak Estimate for NBIX FY2024 Earnings - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Buy" at StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Nov 02, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

abrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Neurocrine shares target upgraded, market perform rating on positive outlook By Investing.com - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Mirae Asset Global Investments Co. Ltd. Acquires 9,601 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Earnings call: Neurocrine Biosciences reports strong Q3 growth, plans ahead - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Neurocrine: Q3 Earnings Snapshot - The Pioneer

Oct 31, 2024
pulisher
Oct 31, 2024

Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Forsta AP Fonden Sells 10,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight - Yahoo Finance

Oct 31, 2024

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Neurocrine Biosciences Inc (NBIX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Boyer David W.
Chief Corp. Affairs Officer
Sep 13 '24
Sale
121.88
3,461
421,828
1,672
$58.78
price down icon 0.54%
$82.47
price down icon 1.14%
$13.00
price up icon 1.33%
$13.45
price down icon 3.79%
$76.22
price down icon 0.79%
大文字化:     |  ボリューム (24 時間):